BioMerieux, Knome Team on Sequencing-Based MDx

The French diagnostics firm, which is targeting the development of sequencing-based diagnostics for cancer and infectious diseases, also has made a $5 million equity investment in Knome.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.